Copenhagen, Denmark; April 24, 2008 – Following Genmab A/S’ (OMX: GEN) Annual General Meeting on April 23 the Board convened and constituted itself with dr. Michael B. Widmer as Chairman and dr. Anders Gersel Pedersen as Deputy Chairman.

Subsequently, on the meeting today the Board decided to issue 715,600 warrants to employees of the company as well as the company’s subsidiaries and to a member of management.

The exercise price for each warrant is DKK 254.00. Each warrant entitles the owner to subscribe one share of nominally DKK 1. On the basis of an exercise price of DKK 254.00 and by application of the Black-Scholes formula, the average value of each warrant can be calculated as DKK 77.78 based on an interest rate of 3.73% and the historical volatility of Genmab A/S shares calculated at 24.93%.

The warrants vest in blocks of 25% one, two, three and four years after the grant date, and all warrants expire at the tenth anniversary of the grant date. The new warrants were granted pursuant to the warrant plan adopted by the board on August 3, 2004. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under the heading ‘warrant scheme’.